A Data-Driven Analysis of Core Dermocosmetic Formulation Patterns for Inflammatory and Barrier-Impaired Skin Conditions

Dermocosmetic products for chronic inflammatory and barrier-impaired skin conditions sit in an underexamined space between cosmetics and pharmaceutical care: widely marketed, yet what actually drives their formulation is rarely made explicit or checked against evidence-based standards. This study analyzes 73 products across six major indications involving chronic inflammatory and barrier-impaired skin conditions, with ingredient composition data extracted directly from product packaging and manufacturer documentation and analyzed using ingredient-level profiling and benchmarking against current dermatology guidelines. The results identify a stable, shared formulation core across product categories, with distinct therapeutic adaptations layered on top: ceramide-rich barrier support in atopic dermatitis, mechanism-specific actives distinguishing psoriasis, rosacea and wound-healing formulas. Guideline comparison surfaces both strong alignment and specific gaps, including under-used, well-evidenced ingredients in xerosis products and guideline-flagged irritants present in sensitive-skin formulations. Together, these findings offer manufacturers a validated formulation baseline and a way to spot genuine innovation gaps, give clinicians a mechanism-based reference for product selection and help consumers gain a clearer, evidence-anchored basis for evaluating products in an increasingly crowded and claims-saturated market. The methodology is designed for reuse, offering a practical foundation for evidence-based advancement across formulation, clinical practice and product choice in dermocosmetics.